CD8A and cancer: Conversely, CD8+ was strongly associated with increased survival in oropharyngeal cancer (Figure 5), in both HPV-negative (pooled HR = 0.39; 95% CI:0.16–0.93) and HPV-positive cancers (pooled HR = 0.40; 95% CI:0.21–0.76 on tumor samples and pooled HR = 0.34; 95% CI:0.15–0.77 on stromal samples) with HPV status being determined by both p16 and DNA in all studies with exception of study by Solomon et al. [37] which defined HPV positivity based on p16 immunostaining alone.